enGene Therapeutics ($ENGN) Insider Trading & Smart Money Activity
enGene Therapeutics Inc. ($ENGN) has 9 insider trades and 2 analyst ratings on file. In the last 12 months on the open market, 1 insider bought ($10.05K) and no insider sold, net +$10.05K.
- Insider buyers (12 mo)
- 1
- Insider sellers (12 mo)
- 0
- Net insider $ (12 mo)
- +$10.05K
- Congress trades (12 mo)
- 0
- 13F moves on file
- 0
- Analyst ratings on file
- 2
ENGN insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q3 2026 | 1 · $10.05K | 0 | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All ENGN insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Insider | Grossman WilliamInterim Chief Medical Officer | Buy (Open-market buy) | 5.10K sh | $10.05K | -4.9% | — | |||||
| Insider | Lota Zoth | Buy (Grant or award) | 31K sh | -2.3% | +9.7% | Read | |||||
| Insider | Wouter Joustra | Buy (Grant or award) | 31K sh | -2.3% | +9.7% | Read | |||||
| Insider | Heffernan Michael Thomas | Buy (Grant or award) | 31K sh | -2.3% | +9.7% | Read | |||||
| Insider | Paul Hastings | Buy (Grant or award) | 31K sh | -2.3% | +9.7% | Read | |||||
| Insider | William GrossmanInterim Chief Medical Officer | Buy (Grant or award) | 231K sh | -2.3% | +9.7% | Read | |||||
| Insider | Richard Glickman | Buy (Grant or award) | 31K sh | -2.3% | +9.7% | Read | |||||
| Insider | Gerald Brunk | Buy (Grant or award) | 31K sh | -2.3% | +9.7% | Read | |||||
| Insider | Philip Astley-Sparke | Buy (Grant or award) | 31K sh | -2.3% | +9.7% | Read | |||||
| Analyst | HC Wainwright | Reiterates to buy | PT $4 | -2.3% | +9.7% | Read | |||||
| Analyst | HC Wainwright | Reiterates to buy | PT $4 | -2.3% | +9.7% | Read |
1W / 1M / 6M = how ENGN moved from the trade or filing date.
Insider trading in ENGN: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Grossman William | Interim Chief Medical Officer | 1 | +$10.05K | Sep 22, 2026 | |
| Lota Zoth | 1 | — | Jun 16, 2026 | ||
| Wouter Joustra | 1 | — | Jun 16, 2026 | ||
| Heffernan Michael Thomas | 1 | — | Jun 16, 2026 | ||
| Paul Hastings | 1 | — | Jun 16, 2026 | ||
| William Grossman | Interim Chief Medical Officer | 1 | — | Jun 16, 2026 | |
| Richard Glickman | 1 | — | Jun 16, 2026 | ||
| Gerald Brunk | 1 | — | Jun 16, 2026 | ||
| Philip Astley-Sparke | 1 | — | Jun 16, 2026 |
Analyst ratings on ENGN
Frequently asked questions
Are ENGN insiders buying or selling?
Over the last 12 months 1 insider made 1 open-market purchase worth $10.05K and 0 insiders made 0 open-market sales worth $0, a net +$10.05K.
What is the latest insider trade in ENGN?
Grossman William, Interim Chief Medical Officer filed a buy (open-market buy) of 5.10K sh worth $10.05K on Sep 22, 2026.
Other biotechnology stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.